Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 159

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 159
---
 extent permitted
by law, to the extent that these liabilities are not covered by insurance. We have obtained directors’ and officers’ liability
insurance for each of our officers and directors. See “ Item 6. C - Directors, Senior Management and Employees - Board
Practices - Exculpation, insurance and indemnification of office holders.”

90

Gloria License Agreement and Securities Purchase Agreement

On August 27, 2023, we entered into the Gloria License Agreement
with HST and Gloria, collectively, the Purchaser Party, pursuant to which we granted HST an exclusive, royalty-bearing, sublicensable
license with respect to the intellectual property rights and know-how associated with motixafortide in order to develop and commercialize
motixafortide in Asia (other than Israel and certain other countries) and to engage and authorize Gloria to perform services under the
Gloria License Agreement in such territory. In connection with the Gloria License Agreement, on August 27, 2023, we also entered into
a securities purchase agreement with HST and Gloria pursuant to which we agreed to sell and issue to HST, in a private placement, an aggregate
of 170,728 of our ADSs. Aggregate gross proceeds from the sale were approximately $14.6 million. In connection with the closing of the
private placement, Dr. Shaoyu Yan, a nominee of HST, was appointed to our board of directors to serve as one of our Class III directors
until our annual general meeting of shareholders to be held in 2026. The appointment was made effective in November 2023. In addition,
effective as of the annual general meeting to be held in 2026 and for so long as the Purchaser Party is the owner of at least 5% of our
issued and outstanding ordinary shares, the Purchaser Party shall have the right, but not the obligation, to nominate one person for election
by our shareholders to serve as a member of our board of directors, provided that such nominee provides the requisite certifications required
for appointment as a director of a public company under Israeli law.

C. Interests of Experts and Counsel

Not applicable.